2017 FDA New Cancer Treatment Approvals Roundup…So Far
Cancer research is on a roll! It’s a very exciting time for cancer research and drug development. In 2016, the United States Food and Drug Administration (FDA) made 19 new approval for cancer drugs. In 2017, there have already been nine new drugs or new indications for existing drugs approved for cancer treatment by the FDA. Follow the links to the American Society of Clinical Oncology website to learn more about each approval below.
Ibrutinib—relapsed/refractory marginal zone lymphoma
Nivolumab— advanced bladder cancer
Lenalidomide—multiple myeloma maintenance therapy after autologous stem cell transplant
Osimertinib—advanced non-small cell lung cancer with the EGFR T790M mutation
Niraparib—recurrent epithelial ovarian, fallopian tube, or peritoneal cancer
Avelumab—metastatic Merkel call carcinoma (a type of skin cancer)
Ribociclib—hormone receptor positive, HER2-negative advanced breast cancer
Pembrolizumab—relapsed or refractory classical Hodgkin lymphoma
Atezolizumab—initial treatment for advanced bladder cancer
To learn more about the importance of clinical trials and the clinical trials approval process, visit My PearlPoint.